APA (7th ed.) Citation

VK, O., S, A., S, P., A, T., O, E., P, S., . . . KJ, K. (2026). Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies. Molecular oncology, 20(5), 1323. https://doi.org/10.1002/1878-0261.70189

Chicago Style (17th ed.) Citation

VK, Ojala, et al. "Recurrent Cancer-associated ERBB4 Mutations Are Transforming and Confer Resistance to Targeted Therapies." Molecular Oncology 20, no. 5 (2026): 1323. https://doi.org/10.1002/1878-0261.70189.

MLA (9th ed.) Citation

VK, Ojala, et al. "Recurrent Cancer-associated ERBB4 Mutations Are Transforming and Confer Resistance to Targeted Therapies." Molecular Oncology, vol. 20, no. 5, 2026, p. 1323, https://doi.org/10.1002/1878-0261.70189.